Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Share-based Compensation: 2014-2024

Historic Share-based Compensation for Axsome Therapeutics (AXSM) over the last 11 years, with Dec 2024 value amounting to $85.2 million.

  • Axsome Therapeutics' Share-based Compensation rose 6.66% to $23.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.0 million, marking a year-over-year increase of 13.22%. This contributed to the annual value of $85.2 million for FY2024, which is 36.09% up from last year.
  • Latest data reveals that Axsome Therapeutics reported Share-based Compensation of $85.2 million as of FY2024, which was up 36.09% from $62.6 million recorded in FY2023.
  • In the past 5 years, Axsome Therapeutics' Share-based Compensation ranged from a high of $85.2 million in FY2024 and a low of $14.8 million during FY2020.
  • In the last 3 years, Axsome Therapeutics' Share-based Compensation had a median value of $62.6 million in 2023 and averaged $61.9 million.
  • Data for Axsome Therapeutics' Share-based Compensation shows a peak YoY surged of 141.31% (in 2020) over the last 5 years.
  • Axsome Therapeutics' Share-based Compensation (Yearly) stood at $14.8 million in 2020, then skyrocketed by 40.98% to $20.8 million in 2021, then skyrocketed by 81.35% to $37.7 million in 2022, then surged by 65.99% to $62.6 million in 2023, then skyrocketed by 36.09% to $85.2 million in 2024.